Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
91.18
-2.06 (-2.21%)
Oct 3, 2024, 4:00 PM EDT - Market closed
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 124.57, with a low estimate of 105 and a high estimate of 180. The average target predicts an increase of 36.62% from the current stock price of 91.18.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 8 | 8 |
| Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +17.35% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +17.35% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +17.35% | Sep 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +17.35% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $180 | Strong Buy | Reiterates | $180 | +97.41% | Sep 5, 2024 |
Financial Forecast
Revenue This Year
385.61M
from 270.60M
Increased by 42.50%
Revenue Next Year
652.75M
from 385.61M
Increased by 69.28%
EPS This Year
-5.66
from -5.27
EPS Next Year
-2.01
from -5.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 422.1M | 791.1M | 1.8B | ||
| Avg | 385.6M | 652.8M | 1.1B | ||
| Low | 352.2M | 460.4M | 851.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 56.0% | 105.1% | 168.4% | ||
| Avg | 42.5% | 69.3% | 73.3% | ||
| Low | 30.1% | 19.4% | 30.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.68 | 1.21 | 10.03 | ||
| Avg | -5.66 | -2.01 | 4.45 | ||
| Low | -6.28 | -4.95 | -2.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.